Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;25(7):494-504.
doi: 10.1016/j.clml.2025.01.014. Epub 2025 Jan 25.

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

David F Moreno  1 , Albert Oriol  2 , Javier de la Rubia  3 , Miguel T Hernández  4 , María Belén Iñigo  5 , Luis Palomera  6 , Felipe de Arriba  7 , Yolanda González  8 , Ana Isabel Teruel  9 , Jordi López Pardo  10 , Ana López de la Guía  11 , Antonia Sampol  12 , Rafael Ríos-Tamayo  13 , Anna Sureda  14 , Norma C Gutiérrez  15 , Maria-Jose Calasanz  16 , María Luisa Martín Ramos  17 , María Victoria Mateos  15 , Jesús San Miguel  16 , Juan José Lahuerta  17 , Joan Bladé  1 , Laura Rosiñol  18 ; PETHEMA/GEM group
Affiliations

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

David F Moreno et al. Clin Lymphoma Myeloma Leuk. 2025 Jul.

Abstract

Purpose: Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11;14) treated with novel agents.

Materials and methods: We analyzed 240 NDMM transplant eligible (TE) patients who received triplet induction regimen in the GEM05MENOS65 (bortezomib, thalidomide and dexamethasone - VTD) and GEM2012 (bortezomib, lenalidomide and dexamethasone - VRD) clinical trials.

Results: t(11;14) and standard risk (SR) non-t(11;14) were prevalent in 51 (21%) and 189 (79%) patients, respectively. Patients with t(11;14) treated with VTD had a lower overall response rate (ORR) (84% vs. 97%, P = .044) and lower negative minimal residual disease (MRD) (7.7% vs 35.1%, P = .049) after induction, as compared to SR non-t(11;14), while there were no differences in ORR (87% vs. 89%) or negative MRD (13.2% vs. 24.4%, P = .2) for these 2 subgroups in patients treated with VRD. The presence of t(11;14) impacted negatively on PFS in patients with VTD (hazard ratio 2.70; P = .005), while no differences were observed in those treated with VRD.

Conclusion: TE NDMM patients harboring t(11;14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.

Keywords: Cytogenetics; Induction; Multiple myeloma; Transplant; t(11;14).

PubMed Disclaimer

Conflict of interest statement

Disclosure A.O. has received honoraria for lectures from and serves on the advisory boards of Janssen, Bristol Myers Squibb-Celgene, Amgen, GlaxoSmithKline, Sanofi, and Pfizer. J.S.M. has received honoraria and consulting services fee from and served on the advisory boards of AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Haemalogix, Janssen, Karyopharm, Merck Sharp & Dohme, Novartis, Takeda, Regeneron, Roche, Sanofi, SecuraBio, and Clínica Universitaria de Navarra. J.J.L. has received consultancy fees and/or has participated on advisory board of BMS, Sanofi, Amgen and Janssen; and has received travel expenses from Celgene and Pfizer. L.R.: honoraria for lectures and advisory boards from Janssen, BMS-Celgene, Amgen, Takeda, Sanofi, GSK, Menarini. J.B.: honoraria for lectures and advisory boards from Janssen, BMS-Celgene, Amgen, Takeda, Oncopeptides. J.dl.R.: honoraria for lectures and advisory boards from Janssen, BMS-Celgene, GSK, Pfizer, Amgen, Menarini, Sanofi. L.P: honoraria for lectures and advisory boards from Janssen, Amgen, Sanofi, GSK. M.V.M.: honoraria derived from lectures and participation in advisory boards for Johnson and Johnson, Celgene-BMS, GSK, Sanofi, Pfizer, Stemline-Menarini, Kite, Regeneron, and Amgen. R.R.T.: Honoraria for lectures and advisory board from Amgen BMS, GSK Janssen, Sanofi, and The Binding Site. M.J.C.: honoraria derived from lectures and participation in advisory boards: Celgene-BMS, GSK, Sanofi, Pfizer, Amgen, Novartis, JAZZ Pharmaceuticals, and Astellas Pharma. A.S.: honoraria from Takeda, BMS/Celgene, MSD, Janssen, Amgen, Novartis, Gilead Kite, Sanofi, Roche, GenMab, Abbvie, Jazz Pharmaceuticals, consultancy from Takeda, BMS/Celgene, Novartis, Janssen, Gilead, Sanofi, GenMab, Abbvie, speaker's Bureau for Takeda and research support from Takeda. M.B.I.: honoraria derived from lectures and participation in advisory boards for Janssen, Celgene-BMS, GSK, Sanofi and Amgen. F.d.A.: honoraria for lectures and advisory boards from Janssen, Bristol-Myers-Squibb (Celgene), Amgen, GlaxoSmithKline, Sanofi and Takeda. N.C.G.: honoraria from Janssen and Amgen, and travel grants from Gilead. The remaining authors have nothing to disclose.

MeSH terms